194 related articles for article (PubMed ID: 37987370)
1. Use of Farnesyl Transferase Inhibitors in an Ageing Model in
Brandt A; Petrovsky R; Kriebel M; Großhans J
J Dev Biol; 2023 Oct; 11(4):. PubMed ID: 37987370
[TBL] [Abstract][Full Text] [Related]
2. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
3. The farnesylated nuclear proteins KUGELKERN and LAMIN B promote aging-like phenotypes in Drosophila flies.
Brandt A; Krohne G; Grosshans J
Aging Cell; 2008 Aug; 7(4):541-51. PubMed ID: 18494863
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
5. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
6. Reversal of age-dependent nuclear morphology by inhibition of prenylation does not affect lifespan in Caenorhabditis elegans.
Bar DZ; Gruenbaum Y
Nucleus; 2010; 1(6):499-505. PubMed ID: 21327093
[TBL] [Abstract][Full Text] [Related]
7. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
10. Gliotoxin reverses age-dependent nuclear morphology phenotypes, ameliorates motility, but fails to affect lifespan of adult Caenorhabditis elegans.
Bar DZ; Neufeld E; Feinstein N; Gruenbaum Y
Cell Motil Cytoskeleton; 2009 Oct; 66(10):791-7. PubMed ID: 19235201
[TBL] [Abstract][Full Text] [Related]
11. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
12. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
13. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
14. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Shafry DD; Gordon LB; Djabali K
Oncotarget; 2017 Sep; 8(39):64809-64826. PubMed ID: 29029393
[TBL] [Abstract][Full Text] [Related]
15. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
16. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
[TBL] [Abstract][Full Text] [Related]
17. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
20. Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
Wang Y; Panteleyev AA; Owens DM; Djabali K; Stewart CL; Worman HJ
Hum Mol Genet; 2008 Aug; 17(15):2357-69. PubMed ID: 18442998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
